A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea. (1st February 2022)
- Record Type:
- Journal Article
- Title:
- A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea. (1st February 2022)
- Main Title:
- A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea
- Authors:
- Ji, Miaomiao
Yuan, Ming
Jiao, Xue
Li, Qiuju
Huang, Yufei
Li, Jing
Wang, Guoyun - Abstract:
- Abstract: Purpose: To study the efficacy and safety of the dienogest and the gonadotropin-releasing hormone agonist (GnRH-a) in symptomatic females with uterine adenomyosis. Methods: A total of 127 patients with adenomyosis with a chief complaint of dysmenorrhea were recruited. The first group received 2 mg of dienogest (DNG) daily, whereas the second group received goserelin acetate (GS) (3.6 mg/4 weeks) for 12 weeks. Outpatient follow-up was undertaken after 12 weeks. Results: Among 127 women, 56/63 (88.9%) patients completed the treatment in the DNG group, whereas 62/64 (96.9%) patients completed the treatment in the GS group. A significant decrease in dysmenorrhea symptoms as measured by the visual analog scale (VAS) and Carcinoma antigen125 (CA125) after 12 weeks of treatment was observed in both groups ( p < .001). The hemoglobin of anemic patients did not significantly improve after 12 weeks of treatment ( p ＝0.21) and the uterine volume slightly increased without statistical significance ( p ＝0.10) in the DNG group. Simultaneously, The hemoglobin of anemic patients significantly improved ( p < .001) and the uterine volume significantly decreased ( p < .001) in the GS group. Conclusions: Dienogest effectively alleviates the symptoms of dysmenorrhea in patients with adenomyosis, but it cannot improve the anemia or reduce the size of the uterus. GnRH-a is more effective in improving anemia and reducing the uterine volume in patients with adenomyosis. TRIALAbstract: Purpose: To study the efficacy and safety of the dienogest and the gonadotropin-releasing hormone agonist (GnRH-a) in symptomatic females with uterine adenomyosis. Methods: A total of 127 patients with adenomyosis with a chief complaint of dysmenorrhea were recruited. The first group received 2 mg of dienogest (DNG) daily, whereas the second group received goserelin acetate (GS) (3.6 mg/4 weeks) for 12 weeks. Outpatient follow-up was undertaken after 12 weeks. Results: Among 127 women, 56/63 (88.9%) patients completed the treatment in the DNG group, whereas 62/64 (96.9%) patients completed the treatment in the GS group. A significant decrease in dysmenorrhea symptoms as measured by the visual analog scale (VAS) and Carcinoma antigen125 (CA125) after 12 weeks of treatment was observed in both groups ( p < .001). The hemoglobin of anemic patients did not significantly improve after 12 weeks of treatment ( p ＝0.21) and the uterine volume slightly increased without statistical significance ( p ＝0.10) in the DNG group. Simultaneously, The hemoglobin of anemic patients significantly improved ( p < .001) and the uterine volume significantly decreased ( p < .001) in the GS group. Conclusions: Dienogest effectively alleviates the symptoms of dysmenorrhea in patients with adenomyosis, but it cannot improve the anemia or reduce the size of the uterus. GnRH-a is more effective in improving anemia and reducing the uterine volume in patients with adenomyosis. TRIAL REGISTRATION: ChiCTR1900024958 … (more)
- Is Part Of:
- Gynecological endocrinology. Volume 38:Number 2(2022)
- Journal:
- Gynecological endocrinology
- Issue:
- Volume 38:Number 2(2022)
- Issue Display:
- Volume 38, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 38
- Issue:
- 2
- Issue Sort Value:
- 2022-0038-0002-0000
- Page Start:
- 164
- Page End:
- 169
- Publication Date:
- 2022-02-01
- Subjects:
- Adenomyosis -- dienogest -- GnRH-a
Endocrine gynecology -- Periodicals
Generative organs, Female -- Diseases -- Periodicals
618.1 - Journal URLs:
- http://informahealthcare.com/journal/gye ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/09513590.2021.2000961 ↗
- Languages:
- English
- ISSNs:
- 0951-3590
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4233.720000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 20747.xml